37,967 Shares in Exelixis, Inc. (NASDAQ:EXEL) Bought by Mutual Advisors LLC

Mutual Advisors LLC purchased a new stake in Exelixis, Inc. (NASDAQ:EXELFree Report) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 37,967 shares of the biotechnology company’s stock, valued at approximately $911,000.

Other institutional investors also recently bought and sold shares of the company. Clearview Wealth Advisors LLC purchased a new stake in Exelixis during the fourth quarter worth approximately $886,000. Contravisory Investment Management Inc. acquired a new position in shares of Exelixis in the 4th quarter valued at $26,000. Whittier Trust Co. grew its position in shares of Exelixis by 131,150.0% in the 4th quarter. Whittier Trust Co. now owns 10,500 shares of the biotechnology company’s stock valued at $252,000 after buying an additional 10,492 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in Exelixis by 244.5% during the 4th quarter. Exchange Traded Concepts LLC now owns 118,359 shares of the biotechnology company’s stock worth $2,839,000 after acquiring an additional 83,999 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its position in Exelixis by 94.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 110,426 shares of the biotechnology company’s stock valued at $2,413,000 after acquiring an additional 53,641 shares during the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Stifel Nicolaus boosted their target price on Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a report on Friday, February 2nd. Royal Bank of Canada increased their price objective on Exelixis from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Barclays raised their target price on shares of Exelixis from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 30th. JMP Securities reiterated a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a research report on Thursday, December 14th. Finally, BTIG Research started coverage on shares of Exelixis in a research report on Tuesday, December 19th. They set a “buy” rating and a $27.00 price objective on the stock. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $26.29.

Get Our Latest Report on EXEL

Insider Buying and Selling

In other Exelixis news, Director David Edward Johnson bought 190,000 shares of Exelixis stock in a transaction on Wednesday, February 21st. The stock was bought at an average price of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the acquisition, the director now owns 1,100,730 shares in the company, valued at $22,785,111. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Patrick J. Haley sold 47,020 shares of Exelixis stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $21.45, for a total transaction of $1,008,579.00. Following the completion of the transaction, the executive vice president now directly owns 384,866 shares of the company’s stock, valued at $8,255,375.70. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David Edward Johnson bought 190,000 shares of the stock in a transaction on Wednesday, February 21st. The stock was purchased at an average cost of $20.70 per share, for a total transaction of $3,933,000.00. Following the acquisition, the director now directly owns 1,100,730 shares of the company’s stock, valued at approximately $22,785,111. The disclosure for this purchase can be found here. 2.90% of the stock is currently owned by corporate insiders.

Exelixis Stock Down 0.4 %

Shares of Exelixis stock opened at $23.61 on Wednesday. The firm has a market cap of $7.16 billion, a price-to-earnings ratio of 36.89, a price-to-earnings-growth ratio of 0.63 and a beta of 0.53. Exelixis, Inc. has a 52-week low of $18.08 and a 52-week high of $24.34. The company’s 50-day simple moving average is $21.96 and its 200-day simple moving average is $21.96.

Exelixis (NASDAQ:EXELGet Free Report) last released its earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. The company had revenue of $479.65 million for the quarter, compared to analysts’ expectations of $481.23 million. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. Equities research analysts anticipate that Exelixis, Inc. will post 1.22 EPS for the current year.

Exelixis Profile

(Free Report)

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Further Reading

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXELFree Report).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.